Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
- Author(s)
- Han, JX; Garg, A; Koh, MJ; Lenart, A; Boussi, L; Barnes, J; Sorial, M; Miranda, E; McCabe, SM; Chiattone, C; Peng, L; Stuver, R; Singh, S; Merrill, M; Eche-Ugwu, IJ; Jacobsen, E; Gabler, J; Kim, Y; Fernandez Turizo, MJ; Shet, T; MacVicar, CT; Sridhar, E; Jain, H; Disciullo, A; Sengar, M; Chopra, K; van der Weyden, C; Murdashvili, T; Nwodo, E; Foss, F; Koh, MJ; Horwitz, SM; Manni, M; Civallero, M; Skrypets, T; Lymboussaki, A; Federico, M; Kim, JS; Cho, JY; Eipe, T; Shetty, A; Saha, S; Prince, HM; Hamouche, R; Gentilini, M; Casadei, B; Zinzani, PL; Okatani, T; Yoshida, N; Yoon, SE; Kim, WS; Panchoo, G; Mohamed, Z; Verburgh, E; Alturas, JC; Al-Mansour, M; Ford, J; Cabrera, ME; Ku, A; Bhagat, G; Ma, H; Sawas, A; Kariya, KM; Iwasaki, M; Bhanushali, F; O'Connor, OA; Marchi, E; Shen, C; Shah, D; Jain, S;
- Details
- Publication Year 2025-02-11,Volume 9,Issue #3,Page 583-602
- Journal Title
- Blood Advances
- Publication Type
- Research article
- Abstract
- Variances in global access to drugs and treatment practices make it challenging to understand the benefit of contemporary therapies in patients with relapsed and refractory (R/R) mature T-cell and natural killer-cell lymphomas (MTCL and MNKCL). We conducted an international retrospective cohort study of 925 patients with R/R MTCL and MNKCL. In peripheral T-cell lymphoma-not otherwise specified and anaplastic lymphoma kinase-negative anaplastic large cell lymphoma (ALK- ALCL), patients with relapsed lymphoma demonstrated a superior median overall survival (OS) relative to refractory from the time of second-line treatment. We identified several independent predictors of OS for R/R lymphoma including age >60 years, primary refractory disease, histological subtype other than angioimmunoblastic T-cell lymphoma (AITL), extranodal sites >1, Ki67 ≥40%, and absolute lymphocyte count less than the lower limit of normal. A multivariable model incorporating these formed the basis for a prognostic index for R/R TCL, in which patients are stratified into low-risk (0-1 risk factor), intermediate-risk (2-3 risk factors), or high-risk (≥4 risk factors) groups, which were associated with 3-year OS of 57.14%, 23.3%, and 7%, respectively. Patients received either a "novel" single agent (SA; 35%) or cytotoxic chemotherapy (CC; 60%) for their second-line treatment. Higher progression-free survival was observed with SA over CC for the entire cohort with a higher 3-year OS in AITL and ALK- ALCL. Among the SA, small-molecule inhibitors demonstrated OS advantage relative to CC in AITL. Our results highlight continued efficacy of novel drugs globally and the potential of a new prediction model in informing heterogeneous prognosis within the R/R population of MTCL and MNKCL.
- Publisher
- American Society of Hematology
- Keywords
- Humans; Prognosis; Male; Female; Middle Aged; Adult; Retrospective Studies; Aged; Treatment Outcome; *Lymphoma, T-Cell/mortality/therapy/drug therapy/diagnosis/pathology; Lymphoma, Extranodal NK-T-Cell/therapy/mortality/diagnosis/drug therapy; Adolescent; Young Adult
- Department(s)
- Haematology
- Publisher's Version
- https://doi.org/10.1182/bloodadvances.2024014674
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-11-28 05:45:53
Last Modified: 2025-02-04 07:05:25